Find Reports

Select Report Type

Reimbursement Review

Displaying 76 - 100 of 1426

Please scroll or swipe to the right to view the full content.

Title	Brand Name	Generic Name	Files	Therapeutic Area	Recommendation Type	Status	Submission Date	Recommendation Date Sort ascending	Project Number
Nivolumab and Ipilimumab	N/A	Nivolumab and Ipilimumab	Recommendation and Reasons Responses to Questions From the Drug Programs Clinical and Pharmacoeconomic combined Report Stakeholder Input	Melanoma (Skin)	Reimburse with clinical criteria and/or conditions	Complete	Oct 16, 2023	Aug 1, 2024	PX0347-000
Nab-paclitaxel	N/A	Nab-paclitaxel	Recommendation and reasons Responses to Questions From the Drug Programs Clinical and Pharmacoeconomic Combined Report Patient and Clinician Group Input	Solid tumours	Reimburse with clinical criteria and/or conditions	Complete	Oct 16, 2023	Jul 24, 2024	PX0348-000
relugolix	Orgovyx	relugolix	Recommendation and Reason Clinical and Pharmacoeconomic Combined Report Stakeholder feedback on Draft Recommendation Patient and Clinician Group input	Advanced prostate cancer	Reimburse with clinical criteria and/or conditions	Complete	Nov 14, 2023	Jul 22, 2024	PC0342-000
atogepant	Qulipta	atogepant	Recommendation and Reason Clinical and Pharmacoeconomic Combined Report Feedback on Draft Recommendation Patient and Clinician Group input	Migraine, prevention	Reimburse with clinical criteria and/or conditions	Complete	Dec 21, 2023	Jul 15, 2024	SR0817-000
pembrolizumab	Keytruda	pembrolizumab	Recommendation and Reason Clinical and Pharmacoeconomic Combined Report Feedback on Draft Recommendation Patient and Clinician Group input	Biliary tract carcinoma	Reimburse with clinical criteria and/or conditions	Complete	Dec 7, 2023	Jul 11, 2024	PC0344-000
Endometrial Cancer			Final Report	Endometrial Cancer		Complete		Jun 27, 2024	PH0045-000
NSCLC without actionable oncog...			Final Report	NSCLC without actionable oncogenic alteration		Complete		Jun 27, 2024	PH0046-000
pembrolizumab	Keytruda	pembrolizumab	Recommendation and Reason Patient and Clinician Group input Clinical and Pharmacoeconomic Combined Report Stakeholder feedback on Draft Recommendation	Gastric or gastroesophageal junction adenocarcinoma	Reimburse with clinical criteria and/or conditions	Complete	Nov 22, 2023	Jun 26, 2024	PC0343-000
aflibercept 8mg/0.07mL	Eylea HD	aflibercept 8mg/0.07mL	Recommendation and Reasons Patient and Clinician Group input Clinical, Pharmacoeconomic and Ethics combined Report Stakeholder feedback on Draft Recommendation	diabetic macular edema	Reimburse with clinical criteria and/or conditions	Complete	Aug 18, 2023	Jun 5, 2024	SR0813-000
aflibercept 8mg/0.07mL	Eylea HD	aflibercept 8mg/0.07mL	Recommendation and Reasons Patient and Clinician Group input Clinical and Pharmacoeconomic Combined Report Stakeholder feedback on Draft Recommendation	macular degeneration, age related	Reimburse with clinical criteria and/or conditions	Complete	Aug 18, 2023	Jun 5, 2024	SR0812-000
Cutaneous Melanoma			Final Report Proposed Project Scope	Cutaneous Melanoma		Complete		Jun 4, 2024	PH0042-000
elranatamab	Elrexfio	elranatamab	Recommendation and Reason Patient and Clinician Group input Clinical and Pharmacoeconomic Combined Report Stakeholder feedback on Draft Recommendation	Relapsed or refractory multiple myeloma	Reimburse with clinical criteria and/or conditions	Complete	Nov 9, 2023	May 31, 2024	PC0315-000
epcoritamab	Epkinly	epcoritamab	Recommendation and Reasons Patient and Clinician Group input Clinical and Pharmacoeconomic Combined Report Feedback on Draft Recommendation	Relapsed or refractory diffuse large B-cell lymphoma	Time-limited reimbursement recommendation	Complete	Nov 14, 2023	May 31, 2024	PC0334-000
nivolumab	Opdivo	nivolumab	Recommendation and Reason Clinical and Pharmacoeconomic Combined Report Feedback on Draft Recommendation Patient and Clinician Group input	Stage IIB or IIC melanoma, adjuvant	Reimburse with clinical criteria and/or conditions	Complete	Nov 6, 2023	May 29, 2024	PC0339-000
Colorectal cancer			Final Report	Colorectal cancer		Complete		May 22, 2024	PH0044-000
insulin icodec	Awiqli	insulin icodec	Recommendation and Reason Clinical and Pharmacoeconomic Combined Report Feedback on Draft Recommendation Patient and Clinician Group input	Diabetes mellitus, type 2	Reimburse with clinical criteria and/or conditions	Complete	Oct 18, 2023	May 17, 2024	SR0790-000
bimekizumab	Bimzelx	bimekizumab	Recommendation and Reasons Clinical and Pharmacoeconomic Combined Report Feedback on Draft Recommendation Patient and Clinician Group input	Ankylosing spondylitis	Reimburse with clinical criteria and/or conditions	Complete	Oct 19, 2023	May 16, 2024	SR0809-000
bimekizumab	Bimzelx	bimekizumab	Recommendation and Reason Clinical and Pharmacoeconomic Combined Report Stakeholder Feedback on Draft Recommendation Patient and Clinician Group input	Psoriatic arthritis	Reimburse with clinical criteria and/or conditions	Complete	Oct 5, 2023	May 15, 2024	SR0803-000
metreleptin	Myalepta	metreleptin	Recommendations and Reasons Clinical and Pharmacoeconomic Combined Report Feedback on Draft Recommendation Patient and Clinician Group input	Leptin deficiency in lipodystrophy	Reimburse with clinical criteria and/or conditions	Complete	Jul 25, 2023	May 9, 2024	SR0784-000
tralokinumab	Adtralza	tralokinumab	Recommendation and Reasons Clinical and Pharmacoeconomic Combined Report Stakeholder Feedback on Draft Recommendation Patient and Clinician Group input	atopic dermatitis (AD)	Do not reimburse	Complete	Jun 5, 2023	May 8, 2024	SR0787-000
avatrombopag	Doptelet	avatrombopag	Recommendation and Reasons Clinical and Pharmacoeconomic Combined Report Feedback on Draft Recommendation Patient and Clinician Group input	Chronic immune thrombocytopenia (ITP)	Do not reimburse	Complete	Feb 3, 2022	May 8, 2024	SR0721-000
dostarlimab	Jemperli	dostarlimab	Recommendation and Reasons Patient and Clinician Group input Clinical and Pharmacoeconomic Combined Report Stakeholder feedback on Draft Recommendation	Endometrial cancer	Reimburse with clinical criteria and/or conditions	Complete	Oct 18, 2023	May 3, 2024	PC0325-000
cemiplimab	Libtayo	cemiplimab	Recommendation and Reasons Clinical and Pharmacoeconomic Combined Report Stakeholder Feedback on Draft Recommendation Patient and Clinician Group input	Locally advanced or metastatic NSCLC (first line)	Reimburse with clinical criteria and/or conditions	Complete	Sep 27, 2023	May 2, 2024	PC0331-000
infliximab	Remsima	infliximab	Recommendation and Reason Patient and Clinician Group input Clinical and Pharmacoeconomic Combined Report Stakeholder feedback on Draft Recommendation	Crohn’s disease	Reimburse with clinical criteria and/or conditions	Complete	Oct 4, 2023	Apr 22, 2024	SR0816-000
inclisiran	Leqvio	inclisiran	Recommendation and Reasons Clinical and Pharmacoeconomic Combined Report Feedback on Draft Recommendation Patient and Clinician Group Input	Primary hypercholesterolemia	Do not reimburse	Complete	Sep 19, 2023	Apr 22, 2024	SR0791-001

Health Technology Review

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 76 - 100 of 602

Please scroll or swipe to the right to view the full content.

Title	Description	Files	Last Updated Sort ascending	Project Sub Line	Status	Project Number
Auditory Verbal Therapy for Children with Hearing Loss		Auditory Verbal Therapy for Children with Hearing Loss	Jul 19, 2024	Rapid Review	Completed	RC1542-000
Optimizing ultrasound booking schedules			Jul 16, 2024		In Progress	CM0021-000
Somatropin		Final Report	Jul 12, 2024	Technology Review	Completed	HC0068-000
Trends in Public Drug Plan Expenditures for Patients With Crohn Disease and Ulcerative Colitis Initiating Targeted Immune Modulator Therapy	Our utilization analysis examines the market share and drug expenditures of targeted immune modulators for inflammatory bowel disease across public drug plans in Canada.	Final Report	Jul 11, 2024	Technology Review	Complete	HC0063-000
Optimal installation of DI equipment			Jun 28, 2024		In Progress	CM0013-000
Appraisal of RWE submitted for health technology assessment			Jun 28, 2024		In Progress	MG0028-000
PET-CT Comparisons 2020-2024			Jun 28, 2024		In Progress	CM0006-000
Cystic Fibrosis			Jun 28, 2024		In Progress	HM0005-000
Newborn screening - Drugs for Rare Diseases Strategy			Jun 28, 2024	Technology Review	In Progress	HC0079-000
Methodology for Ethics Analysis in Pharmaceutical Reimbursement Reviews			Jun 28, 2024		In Progress	MG0027-000
Choline Supplementation for Infants, Children, and Pregnant People		Choline Supplementation for Infants, Children, and Pregnant People	Jun 18, 2024	Rapid Review	Completed	RC1531-000
Interferons, Glatiramer Acetate, and Minocycline for Relapsing-Remitting Multiple Sclerosis and Clinically Isolated Syndrome		Interferons, Glatiramer Acetate, and Minocycline for Relapsing-Remitting Multiple Sclerosis and Clinically Isolated Syndrome	Jun 17, 2024	Rapid Review	Completed	RC1540-000
Nabilone for Chronic Non-Cancer Pain		Nabilone for Chronic Non-Cancer Pain	Jun 14, 2024	Rapid Review	Completed	RC1539-000
Infliximab for Immune Checkpoint Inhibitor Therapy-Related Toxicities		Infliximab for Immune Checkpoint Inhibitor Therapy-Related Toxicities	Jun 14, 2024	Rapid Review	Completed	RC1536-000
Minimum Retesting Intervals for Lab Tests	Canada’s Drug Agency partnered with Choosing Wisely Canada to host a multidisciplinary panel of experts to provide guidance on the minimum retesting intervals of laboratory tests that are commonly repeated in hospitals, health authorities, and community laboratories across the country.	Final Guidance Report Technology Review - Minimum Retesting Intervals for Lab Tests Lipase Quick Guide Hemoglobin A1C Quick Guide Thyroid Stimulating Hormone Quick Guide Serum Protein Electrophoresis Quick Guide Antinuclear Antibody Quick Guide	Jun 11, 2024	Technology Review	Completed	HC0078-000
Anticytokine Therapy and Corticosteroids for Cytokine Release Syndrome and for Neurotoxicity Following T-Cell Engager or CAR T-Cell Therapy		Anticytokine Therapy and Corticosteroids for Cytokine Release Syndrome and for Neurotoxicity Following T-Cell Engager or CAR T-Cell Therapy	Jun 7, 2024	Rapid Review	Completed	RC1534-000
Bayesian Hierarchical Models of Basket Trials in the Context of Economic Evaluation		Bayesian Hierarchical Models of Basket Trials in the Context of Economic Evalua…	May 31, 2024	Technology Review	Completed	MH0020-000
Alemtuzumab, Cladribine, Fingolimod, and Natalizumab as First-Line Treatments in Adult Patients With Highly Active Relapsing Multiple Sclerosis		Final Report Project Protocol	May 30, 2024	Health Technology Assessment	Completed	HT0038-000
Drugs for Advanced Renal Cell Carcinoma: A Treatment Pattern Analysis			May 22, 2024	Technology Review	Active	HC0082-000
Newborn Screening for Congenital Cytomegalovirus in Canada	Congenital cytomegalovirus (cCMV) infection is a leading cause of childhood hearing loss. Our report provides a summary about newborn screening for cCMV in Canada, including whether screening is available in each province and territory, and if so, whether screening is universal or targeted.	Final Report	May 22, 2024	Policy Insight	Completed	CY0016-000
Newborn Screening for Congenital Cytomegalovirus		Newborn Screening for Congenital Cytomegalovirus	May 17, 2024	Rapid Review	Completed	RC1533-000
Exploration of the Risk of Suicidality and Self-Harm With Glucagon-Like Peptide-1 Receptor Agonists		Exploration of the Risk of Suicidality and Self-Harm With Glucagon-Like Peptide…Final Summary Report	May 16, 2024	Technology Review	Completed	HC0087-000
Use of MRI and CT in Private Imaging Facilities in Canada (2021-2023)		Use of MRI and CT in Private Imaging Facilities in Canada (2021-2023)	May 7, 2024	CMII Service	Completed	CM0010-000
General Ultrasound Examination Volumes per Sonographer 8-Hour Workday		General Ultrasound Examination Volumes per Sonographer 8-Hour Workday	May 7, 2024	CMII Service	Completed	CM0012-000
Outpatient Nirmatrelvir-Ritonavir and Remdesivir Utilization in Canada		Final Report, April 2024 Summary Report, April 2024	May 3, 2024	Technology Review	Completed	HC0069-000

Horizon Scan

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 76 - 100 of 110

Please scroll or swipe to the right to view the full content.

Title	Files	Last Updated Sort ascending	Project Sub Line	Status	Project Number
New Mechanical Thrombectomy Devices Designed to Treat Venous Thromboembolism	en0023-mechanical-thrombectomy-devices-article.pdf	Oct 22, 2020	Health Technology Update	Completed	EN0023-000
Non-Invasive Ventilation With Helmets for Acute Respiratory Distress Due to COVID-19	Non-Invasive Ventilation With Helmets for Acute Respiratory Distress Due to COV…	Sep 29, 2020	Health Technology Update	Completed	EN0020-000
Robotic Systems for Disinfecting Surfaces in Hospital Rooms and Other Health Care Environments	en0018-robotic-systems-for-disinfecting-surfaces.pdf	Sep 9, 2020	Health Technology Update	Completed	EN0018-000
A Virtual Waiting Room? Technologies That Limit Contact While Maintaining Patient Flow in Medical Practice Settings	en0019-topic1.pdf	Aug 21, 2020	Health Technology Update	Completed	EN0019-000
Salt-Based Technologies to Help Stop the Spread of the Coronavirus		Jun 23, 2020	Health Technology Update	Completed	EN0017-000
Biomarker-Based Point-of-Care Tests for the Evaluation of Mild Traumatic Brain Injury		Jun 23, 2020	Emerging Health Technologies	Completed	EH0084-000
Blood Purification Using Cytokine Adsorbers to Reduce Cytokine Storm in Severe COVID-19 Illness		Jun 18, 2020	Health Technology Update	Completed	EN0017-000
Health Technology Update Issue 26		Jun 12, 2020			EN0016-000
Saliva-Based Tests to Detect Active Severe Acute Respiratory Syndrome Coronavirus 2 Infection		Jun 3, 2020	Health Technology Update	Completed	EN0017-000
Contact Tracing Apps to Identify Potential Exposure to SARS-CoV-2		May 20, 2020	Health Technology Update	Completed	EN0017-000
Health Technology Update - Issue 27		May 20, 2020			EN0017-000
Health Technology Update Issue 27	en0017-htu-issue27.pdf	May 20, 2020			EN0017-000
Smartphone-Connected Ultrasound Devices		Apr 3, 2020	Emerging Health Technologies	Completed	Eh0079-000
Endobronchial Valves for the Treatment of Severe Emphysema		Mar 19, 2020	Emerging Health Technologies	Completed	EH0083-000
Small Molecule Calcitonin Gene-Related Peptide Receptor Antagonists for the Acute Treatment of Migraine		Mar 19, 2020	Emerging Health Technologies	Completed	EH0081-000
Early Identification of Ischemic Stroke		Mar 19, 2020	Emerging Health Technologies	Completed	EH0080-000
Lasmiditan for the Acute Treatment of Migraine		Mar 17, 2020	Emerging Health Technologies	Completed	EH0082-000
Horizon Scan Roundup — 2019		Mar 13, 2020	Roundup	Completed	ER0008-000
Minimally invasive therapies for benign prostatic hyperplasia (BPH)		Feb 18, 2020	Emerging Health Technologies	Completed	EH0078-000
Health Technology Update - Issue 26		Feb 7, 2020		Completed	EN0016-000
Magnetic Resonance-Guided Radiotherapy: MR-Simulation and MR-Linac		Jan 16, 2020	Emerging Health Technologies	Completed	EH0074-000
Magnetic Resonance Guided Radiotherapy: MR-simulation, and MR-linac		Jan 15, 2020		Completed	EH0074-000
Health Technology Update Issue 25		Jan 10, 2020			EN0015-000
Inclisiran: A Small Interfering RNA Molecule for Treating Hypercholesterolemia		Dec 9, 2019	Emerging Health Technologies	Completed	EH0076-000
Health Technology Update - Issue 25		Nov 11, 2019		Completed	EN0015-000

Projects in Progress

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 26 - 27 of 27

View All Reports

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 76 - 100 of 2138

Please scroll or swipe to the right to view the full content.

Title	Files	Last Updated Sort ascending	Project Line	Project Sub Line	Status	Project Number
Extracorporeal Shockwave Therapy for Erectile Dysfunction	Extracorporeal Shockwave Therapy for Erectile Dysfunction	Apr 15, 2025	Health Technology Review	Rapid Review with Expert Input	Active	RD0075-000
risperidone	Patient and Clinician Group Input	Apr 15, 2025	Reimbursement Review		Active	SR0879-000
belzutifan	Patient and Clinician Group Input	Apr 15, 2025	Reimbursement Review		Active	PC0386-000
avapritinib	Recommendation and Reasons Patient and Clinician Group input Clinical and Pharmacoeconomic Combined Report Feedback on Draft Recommendation	Apr 15, 2025	Reimbursement Review		Complete	PC0335-000
bimekizumab	Patient and Clinician Group input	Apr 14, 2025	Reimbursement Review		Active	SR0856-000
ravulizumab	Recommendation and Reason Patient and Clinician Group input	Apr 14, 2025	Reimbursement Review		Active	SR0855-000
zilucoplan	Recommendation and Reason Patient and Clinician Group Input	Apr 14, 2025	Reimbursement Review		Active	SR0838-000
dupilumab	Patient and Clinician Group Input	Apr 14, 2025	Reimbursement Review		Active	SR0876-000
guselkumab	Patient and Clinician Group input	Apr 14, 2025	Reimbursement Review		Active	SR0874-000
nemolizumab	Patient and Clinician Group Input	Apr 14, 2025	Reimbursement Review		Active	SR0869-000
belantamab mafodotin, pomalidomide, dexamethasone	Patient and Clinician Group Input	Apr 14, 2025	Reimbursement Review		Active	PC0380-000
Evidence Review for Brineura (cerliponase alfa)	Proposed Scope	Apr 11, 2025	Health Technology Review	Technology Review	Active	HC0106-000
dabrafenib trametinib	Draft Recommendation and Reasons Draft Responses to the Questions from the Drug Programs Draft Clinical & Pharmacoeconomic Combined Report Draft Combined Report Supplemental Material Proposed Scope	Apr 11, 2025	Reimbursement Review		Active	PX0375-000
regorafenib	Draft Recommendation Draft Responses to the Questions from the Drug Programs Draft Clinical & Pharmacoeconomic Combined Report Draft Combined Report Supplemental Material Proposed Scope	Apr 11, 2025	Reimbursement Review		Active	PX0374-000
Dabrafenib trametinib	Draft Recommendations & Reasons Draft Responses to the Questions from the Drug Programs Clinical & Pharmacoeconomic Combined Report Combined Report Supplemental Material Proposed Scope	Apr 11, 2025	Reimbursement Review		Active	PX0373-000
relugolix, estradiol, and norethindrone acetate	Patient and Clinician Group Input	Apr 11, 2025	Reimbursement Review		Active	SR0885-000
durvalumab	Patient and Clinician Group input	Apr 11, 2025	Reimbursement Review		Active	PC0372-000
lemborexant		Apr 11, 2025	Reimbursement Review		Received	SR0895-000
Cabozantinib for 2L Renal Cell Carcinoma	Cabozantinib for 2L Renal Cell Carcinoma	Apr 9, 2025	Health Technology Review	Rapid Review	Completed	RC1573-000
nemolizumab	Patient and Clinician Group input	Apr 9, 2025	Reimbursement Review		Active	SR0861-000
Nivolumab and ipilimumab		Apr 9, 2025	Reimbursement Review		Pending	PC0420-000
ruxolitinib	Draft Recommendation	Apr 9, 2025	Reimbursement Review		Active	SR0807-000
spesolimab	Recommendation and Reasons Patient and Clinician Group input Clinical and Pharmacoeconomic Combined Report Feedback on Draft Recommendation	Apr 7, 2025	Reimbursement Review		Complete	SR0844-000
exagamglogene autotemcel	Recommendation and Reasons Patient and Clinician Group Input	Apr 7, 2025	Reimbursement Review		Active	SG0831-000
exagamglogene autotemcel	Recommendation and Reasons Clinical and Pharmacoeconomic Combined Report Feedback on Draft Recommendation Patient and Clinician Group Input	Apr 7, 2025	Reimbursement Review		Complete	SG0830-000

Provisional Funding Algorithm

Displaying 76 - 81 of 81

Please scroll or swipe to the right to view the full content.

Title	Tumour Type Sort descending	Therapeutic Area	Files	Project Number	Project Status	Final Recommendation/Report
Myelofibrosis	Other	Myelofibrosis	Final Report	PH0069-000	Complete	Apr 4, 2025
Mesothelioma	Other	Mesothelioma	Proposed Scope	PH0077-000	Active
Cutaneous Melanoma	Skin & Melanoma	Cutaneous Melanoma	Final Report Proposed Project Scope	PH0042-000	Complete	Jun 4, 2024
Melanoma	Skin & Melanoma	Melanoma	Proposed Scope	PH0072-000	Open for Input
Cutaneous Melanoma	Skin & Melanoma	Cutaneous Melanoma	Final Report	PH0049-000	Complete	Aug 1, 2024
Melanoma	Skin & Melanoma	Melanoma	Final Report	PH0022-000	Complete	Feb 6, 2023